Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.7K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

725
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
725
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

4.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
4.3K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

5.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nuclear export of R-loop by the DDX1 and XPO1 complex promotes senescence-associated secretory phenotype and inflammaging.

Nature aging·2026
Same author

αKG-mediated carnitine synthesis drives DNA repair via histone acetylation.

Nature·2026
Same author

Cross-assay RNA modeling reveals cancer biomarkers.

bioRxiv : the preprint server for biology·2026
Same author

On the predictability of progression-free survival in ovarian cancer from NanoString gene expression data.

bioRxiv : the preprint server for biology·2026
Same author

Transcriptomic subtypes in high-grade serous ovarian cancer are driven by tumor cellular composition.

bioRxiv : the preprint server for biology·2026
Same author

Mitochondrial double-stranded RNA fuels pancreatic cancer growth via RIG-I/TLR3 inflammation.

Proceedings of the National Academy of Sciences of the United States of America·2026

Related Experiment Video

Updated: Oct 11, 2025

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

619

The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity.

Jianhuang Lin1, Dajiang Guo1, Heng Liu1

  • 1Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania.

Cancer Immunology Research
|December 1, 2021
PubMed
Summary

The SETDB1-TRIM28 complex suppresses antitumor immunity. Inhibiting this complex boosts CD8+ T cell infiltration and enhances anti-PD-L1 cancer therapy effectiveness by activating the cGAS-STING pathway.

More Related Videos

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

20.3K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.9K

Related Experiment Videos

Last Updated: Oct 11, 2025

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

619
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

20.3K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.9K

Area of Science:

  • Immunology
  • Epigenetics
  • Cancer Biology

Background:

  • The tumor immune microenvironment is crucial for cancer progression.
  • Epigenetic modifications play a significant role in shaping the tumor immune microenvironment.
  • Identifying regulators of antitumor immunity is essential for developing effective cancer therapies.

Purpose of the Study:

  • To identify epigenetic regulators that suppress antitumor immunity.
  • To elucidate the mechanism by which SETDB1-TRIM28 affects immune cell infiltration and response to immunotherapy.
  • To evaluate the therapeutic potential of targeting the SETDB1-TRIM28 complex in cancer.

Main Methods:

  • Conducted an epigenetic CRISPR-Cas9 screen of 1,218 chromatin regulators.
  • Assessed the correlation between SETDB1-TRIM28 expression and CD8+ T cell infiltration.
  • Investigated the effect of SETDB1-TRIM28 inhibition on PD-L1 expression and the cGAS-STING pathway.
  • Utilized a mouse model of ovarian cancer to evaluate the efficacy of SETDB1 knockout combined with anti-PD-L1 therapy.

Main Results:

  • Identified TRIM28 as a suppressor of PD-L1 expression.
  • Demonstrated that SETDB1-TRIM28 complex expression negatively correlates with CD8+ T cell infiltration.
  • Showed that SETDB1-TRIM28 inhibition upregulates PD-L1, activates the cGAS-STING pathway, and increases CD8+ T cell infiltration.
  • Found that SETDB1 knockout enhances antitumor effects of anti-PD-L1 therapy in a cGAS-dependent manner.

Conclusions:

  • The SETDB1-TRIM28 complex is a critical suppressor of antitumor immunity.
  • Inhibition of SETDB1-TRIM28 bridges innate and adaptive immunity by activating the cGAS-STING pathway.
  • Targeting SETDB1-TRIM28 represents a promising strategy to enhance the efficacy of immune checkpoint blockade therapies.